The paper analyses results of conservative and surgical treatment of 65 patients (83 eyes) with peripheral uveitis. For treatment complex therapy was used, including corticosteroids, agents of desensitizing action, antibiotics, enzymes. In a severe course of the process, suprachoroidal irrigations were made by means of corticosteroids, antibiotics, cytostatics. In recurrent peripheral uveitis, for the purpose to block the process, aimed and limiting argon laser coagulation of peripheral foci was used and in case of neovascularization--aimed coagulation of the new-formed vessels. Total stoppage of the inflammatory process with the absence of recurrences within 3 years was achieved in 45 eyes (54.2%). Visible clinical improvement with suppression of inflammation, reduction of the sizes of exudative depositions and active inflammatory foci, tendency to their cicatrization were recorded in 31 eyes (37.4%). In 7 eyes (8.4%) the therapeutic effect was absent.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics, treatment, and outcomes of nivolumab-induced uveitis.
Immunopharmacol Immunotoxicol
January 2025
College of Pharmacy, Changsha Medical University, Changsha, Hunan, 410219, China.
Nivolumab has been linked to occurrences of uveitis, yet the clinical features associated with these episodes remain unclear. This study aimed to explore the clinical characteristics of uveitis induced by nivolumab and to offer guidance for its prevention, diagnosis, and treatment. We conducted a retrospective analysis by gathering case reports related to nivolumab-induced uveitis from both Chinese and English databases, covering the period from inception until September 30, 2024.
View Article and Find Full Text PDFA peptide mimic of SOCS1 modulates equine peripheral immune cells and ocular effector functions : implications for recurrent uveitis.
Front Immunol
January 2025
Microbiology and Cell Science, Institute of Food and Agricultural Science, University of Florida, Gainesville, FL, United States.
Introduction: Recurrent uveitis (RU), an autoimmune disease, is a leading cause of ocular detriment in humans and horses. Equine and human RU share many similarities including spontaneous disease and aberrant cytokine signaling. Reduced levels of SOCS1, a critical regulator of cytokine signaling, is associated with several autoimmune diseases.
View Article and Find Full Text PDFHidradenitis Suppurativa and Peripheral Ulcerative Keratitis.
J Community Hosp Intern Med Perspect
November 2024
Medstar Health Internal Medicine Residency Program, Baltimore, MD, USA.
The co-occurrence of inflammatory eye disease and hidradenitis suppurativa (HS) is uncommon; ocular involvement typically manifests as anterior uveitis. In this report, we present a unique case of peripheral ulcerative keratitis (PUK) where both infectious and rheumatological workup was negative, leading us to consider the possibility of an association between this condition and severe HS. As far as we are aware, there have only been six documented cases of PUK associated with HS.
View Article and Find Full Text PDFIntegrated analysis of genetic, proteinic, and metabolomic alterations in Behcet's disease.
Sci Rep
January 2025
Department of Ophthalmology, Bishan hospital of Chongqing medical university, Bishan Hospital of Chongqing, Chongqing, China, 402760.
Numerous studies have investigated the alterations of genes, proteins, and metabolites in Behcet's disease (BD). By far, little is known about the depiction of panoramic changes underlying this disease. This study purposed to assess the consistently dysregulated genes, proteins, and metabolites in BD across publications using the vote-counting approach.
View Article and Find Full Text PDFA real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.
Sci Rep
January 2025
Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Brodalumab, a humanized monoclonal antibody that targets the interleukin-17 receptor A, is primarily used to manage moderate-to-severe plaque psoriasis. Although it has demonstrated favorable efficacy and safety in clinical trials, the strict inclusion and exclusion criteria may not fully reflect its safety profile in real-world settings. As its use becomes more widespread in clinical practice, understanding its safety in real-world applications is crucial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!